When we must use antipsychotics (NbN D2 receptor blockers), we do whatever we can to avoid side effects from them. This research upside looks at the potential for the new olanzapine-semiglutide combination medication to reduce D2 blocker-related weight gain in children and teens.

This study looked at adjunctive topiramate for weight in a patient population inherently more vulnerable to cardiometabolic disturbance.